Viveve is a non-surgical, clinically proven treatment that safely and comfortably rejuvenates vaginal tissue and improves its responsiveness. Like the skin, vaginal tissue changes over time. When collagen support fibres lose their youthful strength and vitality, a feeling of looseness, especially around the vaginal opening, occurs. Vaginal laxity is an extremely common medical condition caused by ageing, childbirth, genetics and lifestyle. Millions of women suffer silently with vaginal laxity and the resulting loss of sexual sensation and satisfaction.
The Viveve treatment is not a cosmetic procedure; it’s not about how you look—it’s about how you feel. Viveve is a painless procedure performed by a cosmetic physician and designed to treat vaginal laxity and increase physical sensation during intercourse. The treatment takes approximately 45 minutes with no anesthesia or downtime.
Vaginal Rejuvenation Treatment London
How it works
Using patented deep heating and surface cooling techniques with radio frequency energy, the Viveve treatment stimulates the body’s natural collagen formation process. This dual heating and cooling method maintains the patient’s safety and comfort throughout the procedure, all while triggering the regeneration of collagen to tighten and firm the lax skin in the vaginal area.
Women who have had the Viveve treatment agree it works. In fact, 90% of the patients in clinical studies reported significant, sustained tightening, sensation and satisfaction 12 months after treatment.
The Viveve procedure can also treat urinary stress incontinence, also known as involuntary urination. The leakage of urine is a common and distressing issue, which affects many women worldwide and may have a large impact on quality of life. However, it can now be treated in one single session by the Viveve procedure at Revere Clinics.
Who is this right candidate?
If you are a woman suffering from vaginal laxity or/and urinary stress incontinence, the Viveve treatment could be right for you. However, this treatment is contraindicated for patients with either an implantable pacemaker or an Automatic Implantable Cardioverter/Defibrillator (AICD), or any other implantable device.